{"entity":{"id":"nct05949125","kind":"trial","name":"Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)","aka":[],"tldr":"A phase 1 trial of AVC-201 run by AvenCell Europe GmbH, now recruiting.","summary":"Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) is a phase 1 interventional study registered as NCT05949125 by AvenCell Europe GmbH, with 37 participants planned, started 2024-01-03. Conditions recorded: Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory. Interventions recorded: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123 and Allo-RevCAR01-T.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05949125","url":"https://clinicaltrials.gov/study/NCT05949125"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["avc-201"],"companies":["avencell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05949125","phase":"1","setting":"Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo RevCAR01 T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123","sponsor":"AvenCell Europe GmbH","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05949125/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"avc-201","kind":"drug","name":"AVC-201","route":"/drugs/avc-201/"}],"company":[{"id":"avencell-therapeutics","kind":"company","name":"AvenCell Therapeutics","route":"/companies/avencell-therapeutics/"}]}}